

Estrogen Receptor (ER) [1D5]

Concentrated and Prediluted Monoclonal Antibody
901-054-052423

BIOCARE
M E D I C A L

Available Product Formats

Format	Catalog Number	Description	Dilution	Diluent
Concentrate	ACI 054 A, C	0.1, 1.0 mL	1:50-1:100	Van Gogh Yellow
Predilute	API 054 AA	6.0 mL	Ready-to-use	N/A
ONCORE Pro	OPAI 054 T60	60 tests	Ready-to-use	N/A

Intended Use:

For In Vitro Diagnostic Use

Estrogen Receptor (ER) [1D5] is a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of estrogen receptor (ER) protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Summary and Explanation:

Estrogen Receptor (ER) [1D5] is a mouse monoclonal antibody directed against human estrogen receptor protein. ER is a 66 kDa protein that mediates the actions of estrogen in estrogen-responsive tissues. It is a member of a large superfamily of nuclear-hormone receptors that function as ligand-activated transcription factors. The ER gene consists of more than 140 kb of genomic DNA divided into 8 exons. These translate into a protein with six functionally discrete domains, labeled A through F. ER [1D5] reacts with the amino-terminal domain in the A/B region of ER-alpha. This clone has been established to work in formalin-fixed, paraffin-embedded tissues and has been published in numerous breast cancer research studies.

FOR DISTRIBUTION OUTSIDE THE UNITED STATES ONLY.

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a secondary antibody is added to bind to the primary antibody. An enzyme label is then added to bind to the secondary antibody; this detection of the bound antibody is evidenced by a colorimetric reaction.

Source: Mouse monoclonal

Species Reactivity: Human; others not tested

Clone: 1D5

Isotype: IgG1/kappa

Protein Concentration: Call for lot specific Ig concentration.

Epitope/Antigen: Estrogen receptor protein

Cellular Localization: Nuclear

Positive Tissue Control: Breast carcinoma

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Protocol Recommendations (intelliPATH FLX® and manual use):

Peroxide Block: Block for 5 minutes with Peroxidized 1.

Pretreatment Solution (recommended): Reveal or Diva

Pretreatment Protocol:

Heat Retrieval Method:

Preheat the retrieval solution to 95°C for 30 minutes in Decloaking Chamber. Then, place slides into the preheated solution and retrieve under pressure at 95°C for 40 minutes; alternatively, steam tissue sections for 45-60 minutes or use a water bath at 95°C for 40 minutes. Allow solution to cool for 20 minutes then wash in distilled water.

Protein Block (Optional): Incubate for 5-10 minutes at RT with Background Punisher.

Protocol Recommendations (intelliPATH FLX and manual use)

Cont'd:

Primary Antibody: Incubate for 30 minutes at RT.

Polymer: Incubate for 10 minutes at RT with a tertiary polymer.

Chromogen: Incubate for 5 minutes at RT with Biocare's DAB -OR- Incubate for 5-7 minutes at RT with Warp Red.

Counterstain: Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Technical Note:

This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

Protocol Recommendations (ONCORE™ Pro Automated Slide Staining System):

OPAI054 is intended for use with the ONCORE Pro. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Editor should be programmed as follows:

Protocol Name: ER

Protocol Template (Description): IHC Extras template

Dewaxing (DS Buffer Option): DS2-50

Antigen Retrieval (AR Option): AR1, high pH; 101°C

Block Option: Buffer

Reagent Name, Time, Temp.: ER, 30 min., 25°C

Limitations:

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

Quality Control:

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (5)
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (6)
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The SDS is available upon request and is located at <http://biocare.net>.



60 Berry Drive
Pacheco, CA 94553
USA



TP V2 (10/26/2021)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080



EMERGO EUROPE
Westervoortsedijk 60
6827 AT Arnhem
The Netherlands

Estrogen Receptor (ER) [1D5]

Concentrated and Prediluted Monoclonal Antibody
901-054-052423

BIOCARE
M E D I C A L

Troubleshooting:

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

References:

1. Paech K, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. *Science*. 1997 Sep; 277(5331):1508-10.
2. Brock JE, et al. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. *Am J Clin Pathol*. 2009 Sep; 132(3):396-401.
3. Madeira KP, et al. Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer. *Pathol Res Pract*. 2012 Nov; 208(11):657-61.
4. Nadji M, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. *Am J Clin Pathol*. 2005 Jan; 123 (1):21-7.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.



60 Berry Drive
Pacheco, CA 94553
USA



TP V2 (10/26/2021)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080



EMERGO EUROPE
Westervoortsedijk 60
6827 AT Arnhem
The Netherlands